Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Acurx Pharmaceuticals ( (ACXP) ) has provided an announcement.
On May 8, 2025, Acurx Pharmaceuticals entered into a purchase agreement with Lincoln Park Capital Fund, allowing Lincoln Park to buy up to $12 million in shares of Acurx’s common stock. This agreement provides Acurx with the flexibility to sell shares at its discretion over a 24-month period, potentially impacting its funding strategies and market operations. The proceeds from these sales are intended for working capital and general corporate purposes, with certain limitations and conditions outlined in the agreement to ensure compliance with Nasdaq rules.
Spark’s Take on ACXP Stock
According to Spark, TipRanks’ AI Analyst, ACXP is a Underperform.
Acurx Pharmaceuticals’ score reflects the challenges of an early-stage biotech, including lack of revenue and ongoing losses, balanced by strong potential in clinical advancements and regulatory support. Technical indicators suggest weak momentum, and valuation is hindered by financial fundamentals.
To see Spark’s full report on ACXP stock, click here.
More about Acurx Pharmaceuticals
Average Trading Volume: 249,677
Technical Sentiment Signal: Sell
Current Market Cap: $7.64M
For an in-depth examination of ACXP stock, go to TipRanks’ Stock Analysis page.